Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

Compare

9,924 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CRSP Analyst Ratings

Moderate Buy

14 Buy

7 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Crispr

Therapeutics AG

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CRSP Stock 12 Month Forecast

Average Price Target

$69.69

▲(24.25%Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $69.69 with a high forecast of $105.00 and a low forecast of $38.00. The average price target represents a 24.25% change from the last price of $56.09.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,59.8523076923077,63.61461538461539,67.37692307692308,71.13923076923078,74.90153846153846,78.66384615384615,82.42615384615385,86.18846153846154,89.95076923076923,93.71307692307693,97.47538461538461,101.2376923076923,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,57.136153846153846,58.182307692307695,59.22846153846154,60.27461538461539,61.32076923076923,62.36692307692308,63.41307692307692,64.45923076923077,65.50538461538461,66.55153846153846,67.59769230769231,68.64384615384616,{"y":69.69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,54.698461538461544,53.30692307692308,51.91538461538462,50.52384615384616,49.13230769230769,47.74076923076923,46.34923076923077,44.95769230769231,43.566153846153846,42.174615384615386,40.78307692307692,39.39153846153846,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$69.69

Lowest Price Target$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$60

Hold

6.97%

Upside

Reiterated

07/31/25

Crispr Therapeutics AG's stock score reflects the significant financial challenges it faces, particularly regarding revenue and profitability. However, positive corporate events and some technical momentum provide a more balanced outlook, although high volatility and valuation concerns remain.

Tyler Van BurenTD Cowen

TD Cowen

$35→$40

Hold

-28.69%

Downside

Reiterated

08/04/25

Cautious Hold Rating for Casgevy Amid Growth and Upcoming Data ReleasesWe have added CTX310 to our model and increased our PT to $40.

Alec StranahanBank of America Securities

Bank of America Securities

$79→$78

Buy

39.06%

Upside

Reiterated

07/22/25

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

Gil BlumNeedham

Needham

$81

Buy

44.41%

Upside

Reiterated

07/08/25

Crispr Therapeutics AG: Strategic Positioning and Growth Potential in Gene Editing

Liisa BaykoEvercore ISI

Evercore ISI

$99

Buy

76.50%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Crispr Therapeutics AG (CRSP)

Silvan TuerkcanCitizens JMP

Citizens JMP

$86

Buy

53.33%

Upside

Reiterated

06/27/25

Citizens JMP Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$65

Buy

15.89%

Upside

Reiterated

06/27/25

Promising Developments and Strategic Timing Boost Crispr Therapeutics AG's Prospects: A Buy Recommendation by Mitchell Kapoor

Edward TenthoffPiper Sandler

Piper Sandler

$105

Buy

87.20%

Upside

Reiterated

06/27/25

Piper Sandler Remains a Buy on Crispr Therapeutics AG (CRSP)

Geulah LivshitsChardan Capital

Chardan Capital

$82

Buy

46.19%

Upside

Reiterated

06/26/25

Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital

William MaughanClear Street

Clear Street

$45

Hold

-19.77%

Downside

Downgraded

06/26/25

Clear Street downgrades Crispr Therapeutics AG (CRSP) to a Hold

Salveen RichterGoldman Sachs

Goldman Sachs

$47

Hold

-16.21%

Downside

Reiterated

06/26/25

Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Gena WangBarclays

Barclays

$42

Hold

-25.12%

Downside

Reiterated

06/26/25

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/26/25

Buy Rating Affirmed for Crispr Therapeutics AG Due to Promising Clinical Data and Competitive Positioning

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

―

Buy

―

Reiterated

06/26/25

Brookline Capital Markets Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/26/25

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Galapagos (NASDAQ: GLPG) and Pharvaris (NASDAQ: PHVS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$60

Hold

6.97%

Upside

Reiterated

07/31/25

Tyler Van BurenTD Cowen

TD Cowen

$35→$40

Hold

-28.69%

Downside

Reiterated

08/04/25

Cautious Hold Rating for Casgevy Amid Growth and Upcoming Data ReleasesWe have added CTX310 to our model and increased our PT to $40.

Alec StranahanBank of America Securities

Bank of America Securities

$79→$78

Buy

39.06%

Upside

Reiterated

07/22/25

Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities

Gil BlumNeedham

Needham

$81

Buy

44.41%

Upside

Reiterated

07/08/25

Crispr Therapeutics AG: Strategic Positioning and Growth Potential in Gene Editing

Liisa BaykoEvercore ISI

Evercore ISI

$99

Buy

76.50%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Crispr Therapeutics AG (CRSP)

Silvan TuerkcanCitizens JMP

Citizens JMP

$86

Buy

53.33%

Upside

Reiterated

06/27/25

Citizens JMP Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$65

Buy

15.89%

Upside

Reiterated

06/27/25

Promising Developments and Strategic Timing Boost Crispr Therapeutics AG's Prospects: A Buy Recommendation by Mitchell Kapoor

Edward TenthoffPiper Sandler

Piper Sandler

$105

Buy

87.20%

Upside

Reiterated

06/27/25

Piper Sandler Remains a Buy on Crispr Therapeutics AG (CRSP)

Geulah LivshitsChardan Capital

Chardan Capital

$82

Buy

46.19%

Upside

Reiterated

06/26/25

Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital

William MaughanClear Street

Clear Street

$45

Hold

-19.77%

Downside

Downgraded

06/26/25

Clear Street downgrades Crispr Therapeutics AG (CRSP) to a Hold

Salveen RichterGoldman Sachs

Goldman Sachs

$47

Hold

-16.21%

Downside

Reiterated

06/26/25

Goldman Sachs Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

Gena WangBarclays

Barclays

$42

Hold

-25.12%

Downside

Reiterated

06/26/25

Crispr Therapeutics AG (CRSP) Gets a Hold from Barclays

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/26/25

Buy Rating Affirmed for Crispr Therapeutics AG Due to Promising Clinical Data and Competitive Positioning

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

―

Buy

―

Reiterated

06/26/25

Brookline Capital Markets Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/26/25

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (NASDAQ: CRSP), Galapagos (NASDAQ: GLPG) and Pharvaris (NASDAQ: PHVS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

1 Month

xxx

Success Rate

12/18 ratings generated profit

Average Return

+9.43%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.

3 Months

xxx

Success Rate

12/20 ratings generated profit

Average Return

+8.78%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.78% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

11/20 ratings generated profit

Average Return

+10.71%

reiterated a buy rating last month

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +10.71% per trade.

2 Years

xxx

Success Rate

11/20 ratings generated profit

Average Return

+5.12%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.00% of your transactions generating a profit, with an average return of +5.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRSP Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CRSP has received 14 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. CRSP average Analyst price target in the past 3 months is 69.69.

Each month's total comprises the sum of three months' worth of ratings.

CRSP Financial Forecast

CRSP Earnings Forecast

Next quarter’s earnings estimate for CRSP is -$1.30 with a range of -$1.97 to -$0.83. The previous quarter’s EPS was -$2.40. CRSP beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year CRSP has Preformed in-line its overall industry.

CRSP Sales Forecast

Next quarter’s sales forecast for CRSP is $12.77M with a range of $0.00 to $44.36M. The previous quarter’s sales results were $892.00K. CRSP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year CRSP has Preformed in-line its overall industry.

CRSP Stock Forecast FAQ

What is CRSP’s average 12-month price target, according to analysts?

Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is 69.69.

What is CRSP’s upside potential, based on the analysts’ average price target?

Crispr Therapeutics AG has 24.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CRSP a Buy, Sell or Hold?

Crispr Therapeutics AG has a consensus rating of Moderate Buy which is based on 14 buy ratings, 7 hold ratings and 0 sell ratings.

What is Crispr Therapeutics AG’s price target?

The average price target for Crispr Therapeutics AG is 69.69. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $105.00 ,the lowest forecast is $38.00. The average price target represents 24.25% Increase from the current price of $56.09.

What do analysts say about Crispr Therapeutics AG?

Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of CRSP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target

CRSP Analyst Ratings

CRSP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Crispr Therapeutics AG

CRSP Analyst Recommendation Trends

CRSP Financial Forecast

CRSP Earnings Forecast

CRSP Sales Forecast

CRSP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts